- 2x increase in average read length;
- 3-4x improvement in mappable data per SMRT Cell;
- 50-80% reduction in input DNA required; and
- Consensus accuracy of Q50 (99.999%) at substantially lower coverage.
Pacific Biosciences of California, AMAG Pharmaceuticals and Global Blood Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
The healthcare sector was dragged down by reports of price collusion and worse-than-expected third-quarter profits.
Trade-Ideas LLC identified Pacific Biosciences of California (PACB) as a "perilous reversal" (up big yesterday but down big today) candidate